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Neurobiology of Disease

The Complement System Component C5a Produces Thermal
Hyperalgesia via Macrophage-to-Nociceptor Signaling That
Requires NGF and TRPV1
X Leonid P. Shutov,1* X Charles A. Warwick,1* Xiaoyu Shi,2 Aswini Gnanasekaran,1 Andrew J. Shepherd,1,3
Durga P. Mohapatra,1,3 X Trent M. Woodruff,4 J. David Clark,2 and Yuriy M. Usachev1
1

Department of Pharmacology, University of Iowa, Iowa City, Iowa 52242, 2Department of Anesthesia, Veterans Administration Palo Alto Healthcare
System and Stanford University, Palo Alto, California 94305, 3Department of Anesthesiology, Washington University Pain Center, Washington University
School of Medicine, St. Louis, Missouri 63110, and 4School of Biomedical Sciences, University of Queensland, St. Lucia, Queensland 4072, Australia

The complement cascade is a principal component of innate immunity. Recent studies have underscored the importance of C5a and other
components of the complement system in inflammatory and neuropathic pain, although the underlying mechanisms are largely unknown. In particular, it is unclear how the complement system communicates with nociceptors and which ion channels and receptors are
involved. Here we demonstrate that inflammatory thermal and mechanical hyperalgesia induced by complete Freund’s adjuvant was
accompanied by C5a upregulation and was markedly reduced by C5a receptor (C5aR1) knock-out or treatment with the C5aR1 antagonist
PMX53. Direct administration of C5a into the mouse hindpaw produced strong thermal hyperalgesia, an effect that was absent in TRPV1
knock-out mice, and was blocked by the TRPV1 antagonist AMG9810. Immunohistochemistry of mouse plantar skin showed prominent
expression of C5aR1 in macrophages. Additionally, C5a evoked strong Ca 2⫹ mobilization in macrophages. Macrophage depletion in
transgenic macrophage Fas-induced apoptosis mice abolished C5a-dependent thermal hyperalgesia. Examination of inflammatory mediators following C5a injection revealed a rapid upregulation of NGF, a mediator known to sensitize TRPV1. Preinjection of an NGFneutralizing antibody or Trk inhibitor GNF-5837 prevented C5a-induced thermal hyperalgesia. Notably, NGF-induced thermal
hyperalgesia was unaffected by macrophage depletion. Collectively, these results suggest that complement fragment C5a induces thermal
hyperalgesia by triggering macrophage-dependent signaling that involves mobilization of NGF and NGF-dependent sensitization of
TRPV1. Our findings highlight the importance of macrophage-to-neuron signaling in pain processing and identify C5a, NGF, and TRPV1
as key players in this cross-cellular communication.
Key words: C5a; C5aR1; complement; macrophage; NGF; TRPV1

Significance Statement
This study provides mechanistic insight into how the complement system, a key component of innate immunity, regulates the
development of pain hypersensitivity. We demonstrate a crucial role of the C5a receptor, C5aR1, in the development of inflammatory thermal and mechanical sensitization. By focusing on the mechanisms of C5a-induced thermal hyperalgesia, we show that
this process requires recruitment of macrophages and initiation of macrophage-to-nociceptor signaling. At the molecular level,
we demonstrate that this signaling depends on NGF and is mediated by the heat-sensitive nociceptive channel TRPV1. This deeper
understanding of how immune cells and neurons interact to regulate pain processing is expected to facilitate mechanism-based
approaches in the development of new analgesics.

Introduction
The complement system is a critical part of innate immunity and
plays an important role in the recognition and clearance of patho-
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gens. It consists of ⬎30 soluble and membrane-bound proteins that
are rapidly mobilized through a cascade of enzymatic reactions and
participate in host defenses through a range of mechanisms, including direct killing of bacteria, facilitation of phagocytosis, the recr-
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uitment and activation of immune cells, vasodilation, and an increase in vascular permeability (Monk et al., 2007; Wagner and
Frank, 2010; Ricklin and Lambris, 2013;
Holers, 2014). Recent studies have highlighted the importance of the complement
cascade in the nervous system, particularly
in the regulation of nociceptor function and
pain processing (Griffin et al., 2007; Jang et
al., 2010; Ren and Dubner, 2010; LaCroixFralish et al., 2011). An upregulation of several components of the complement system Figure 1. C5aR1 KO significantly reduces inflammatory thermal and mechanical hyperalgesia induced by CFA. A, B, CFA was
in the periphery, DRG, and spinal cord has injected into the plantar surface of either wild-type or C5aR1 KO (BALB/C background) mouse hindpaw. Thermal (A; pawbeen implicated in inflammatory and neu- withdrawal latency; 14 wild-type and 16 C5aR1 KO mice) and mechanical (B; mechanical threshold; 20 wild-type and 20 C5aR1 KO
ropathic pain, whereas inhibition of the mice) sensitivities were measured before (baseline time ⫽ 0) and at various times after the CFA injection. *p ⬍ 0.05, relative to
complement cascade has been reported to wild-type mice (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). **p ⬍ 0.01, relative to wild-type mice
produce analgesic effects in several animal (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
models of chronic pain (Twining et al.,
Here, by using genetic and pharmacological tools, we identify
2005; Griffin et al., 2007; Jang et al., 2011; LaCroix-Fralish et al.,
transient receptor potential vanilloid 1 (TRPV1) as a key molec2011).
ular target of C5a-induced signaling that leads to thermal hyperAmong the many components of the complement system,
algesia. We also demonstrate that macrophages are required for
C5a is perhaps best established as a potent regulator of pain proC5a-induced thermal hyperalgesia, suggesting that macrophagecessing. C5a is a 74 amino acid polypeptide that is rapidly proto-nociceptor communication is involved. Finally, we show that
duced in response to injury or infection by proteolytic cleavage of
NGF, a well-established modulator of TRPV1, is also required
complement protein C5. Each of the three major complement
and acts downstream of C5a and upstream of TRPV1 in the proactivation pathways (i.e., classical, lectin, and alternative) can
posed signaling cascade.
lead to the generation of C5a that acts via a canonical G-protein
coupled receptor, C5aR1 (also known as C5aR or CD88), and
possibly another recently characterized receptor, C5aR2 (also
Materials and Methods
known as C5L2 or GPR77), to enhance immune responses and
Animals. All experiments involving the use of mice and the procedures
produce many other biological effects (Brennan et al., 2012; Klos
used therein were approved by the University of Iowa Institutional Aniet al., 2013; Li et al., 2013; Ricklin and Lambris, 2013; Kemper et
mal Care and Use Committee and were performed in strict accordance
al., 2014). Numerous studies suggest the importance of C5a in
with the National Institutes of Health Guide for the care and use of laboratory animals. Every effort was made to minimize the number of mice
various chronic pain conditions. Indeed, increased production of
used and their suffering. Male C57BL/6J or BALB/C (6 –10 weeks of age)
C5a has been reported in several pathological states associated
mice were housed with food and water ad libitum under a 12 h light/dark
with pain, including rheumatoid arthritis, pancreatitis, inflamcycle. C5aR1 KO (#006845; BALB/C), TRPV1 KO (#003770; C57BL/6J),
matory bowel disease, and surgical trauma (Fosse et al., 1987;
macrophage Fas-induced apoptosis (MAFIA) (#005070; C57BL/6J), and
Roxvall et al., 1989; Jose et al., 1990; Kiener et al., 1998; Grant et
phospholipase C␤2 (PLC␤2) KO (#018064; C57BL/6J) mice were pural., 2002; Bhatia, 2005). Upregulation of C5 and C5a has also been
chased from The Jackson Laboratory.
shown in the animal models of postsurgical pain and neuropathic
Macrophage depletion. For drug-inducible macrophage depletion expain (Griffin et al., 2007; Jang et al., 2011), whereas direct adminperiments, we used transgenic MAFIA mice (Burnett et al., 2004). These
istration of C5a produced prominent thermal and mechanical
mice express a drug-inducible suicide gene under the control of the
sensitization in rodents (Levine et al., 1985; Jang et al., 2010, 2011;
macrophage/monocyte-specific colony-stimulating factor (CSF) 1 receptor (c-fms) promoter, whose activation by the dimerizing compound
Moriconi et al., 2014). Notably, genetic deletion of the C5a preAP20187 (Clontech catalog #635069) triggers Fas-induced apoptosis in
cursor, C5, reduced neuropathic pain (Griffin et al., 2007), and
macrophages and dendritic cells (Burnett et al., 2004; O’Brien et al., 2012;
C5aR1 knock-out (KO) decreased thermal and mechanical senCho
et al., 2014). MAFIA mice do not seem to be depleted of microglia
sitization induced by incision (Liang et al., 2012). Moreover, the
following systemic administration of AP20187, most likely due to poor
administration of C5aR1 antagonists produced analgesic effects
penetration of the compound through the blood– brain barrier (Burnett
in various models of inflammatory and neuropathic pain (Clark
et al., 2004; Wang et al., 2013). Male MAFIA mice were administered
et al., 2006; Ting et al., 2008; Jang et al., 2011; Moriconi et al.,
either 2 mg/kg of AP20187 dissolved in vehicle (10% PEG-400 and 1.7%
2014), highlighting the therapeutic potential of pharmacological
Tween 80 in PBS) or vehicle alone on a daily basis via intraperitoneal
targeting of C5a and C5aR1 for chronic pain management.
injection for 5 d. Behavioral testing and immunohistochemistry were
Despite the growing evidence for the crucial role of C5a in
performed 6 d after the first injection of AP20187 or vehicle.
Behavioral testing. Thermal and mechanical sensitivity was measured
chronic pain, the mechanisms underlying its pronociceptive acby Hargreaves test and von Frey filament threshold calculation, respections have not been delineated. In particular, it is unclear how
tively, as described previously (Schnizler et al., 2008; Jang et al., 2010; Loo
C5a and other complement components signal to nociceptors,
et al., 2012; Mickle et al., 2015b). Briefly, mice were acclimatized to the
and which nociceptive ion channels or receptors they target.
*L.P.S. and C.A.W. contributed equally to this work.
Correspondence should be addressed to Dr. Yuriy M. Usachev, Department of Pharmacology, University of Iowa
Carver College of Medicine, 2-450 BSB, 51 Newton Road, Iowa City, IA 52242. E-mail: yuriy-usachev@uiowa.edu.
DOI:10.1523/JNEUROSCI.3249-15.2016
Copyright © 2016 the authors 0270-6474/16/365056-16$15.00/0

behavioral testing chambers for 2 h per day beginning 3 d before testing.
The Hargreaves testing apparatus was an IITC Plantar Analgesia Meter
(IITC Life Sciences) with the glass tabletop heated to a thermo-neutral
temperature. Nociceptive thermal sensitivity was measured by focusing a
beam of light on the plantar surface of the hindpaw to generate heat. The
time required for the stimulus to elicit withdrawal of the hindpaw (paw
withdrawal latency) was recorded using the programmable digital timer
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was administered into the plantar skin of the
hindpaw 30 min before injection of C5a or
NGF. For systemic administration of the
C5aR1 antagonist, PMX53 (Woodruff et al.,
2002; Proctor et al., 2006; Woodruff et al.,
2006), the drug was dissolved in sterile 5%
glucose/water solution and delivered subcutaneously into the skin of the back of mouse
at a 3 mg/kg dose in a 100 l volume 1 h
before behavioral testing. Efficacy of this
dose of PMX53 has been extensively validated (Woodruff et al., 2002; Proctor et al.,
2006; Jang et al., 2011; Benson et al., 2015).
The individual performing the behavioral measurements was blinded to the
drug treatment and mouse genotype where
applicable.
ELISA measurements. C5a (500 ng in 10 l
PBS) was administered subcutaneously into
the hindpaw as described above. Mice (C57BL/
6J) were killed by cervical dislocation under
isoflurane anesthesia at various time points after injection: 0 (control/baseline), 0.5, 1, 2, 3,
and 24 h (4 mice/time point). A sharp scalpel
was used to remove a 3 ⫻ 8 mm area of skin
from the plantar surface of the hindpaw; the
skin sample was then cut into small pieces using scissors, and then homogenized in buffer
containing 1⫻ Complete Protease Inhibitor
Mixture (Roche Applied Science), 100 mM
Tris/HCl, 1 M NaCl, 4 mM EDTA, 2% Triton
X-100, 0.1% sodium azide using a Polytron homogenizer device. Homogenates were then
centrifuged at 12,000 ⫻ g for 15 min at 4°C, and
the supernatant was collected and used to perform a Pierce BCA total protein assay (Thermo
Scientific) as described by the manufacturer.
Figure 2. C5aR1 significantly contributes to thermal and mechanical hyperalgesia induced by CFA. A, Levels of C5a in skin tissue Samples were then frozen at ⫺80°C until used
from naive wild-type C57BL/6J mice (baseline) or after injection of CFA were measured by ELISA at the indicated time points (n ⫽ 5 for ELISA. NGF and prostaglandin E2 (PGE2)
or 6 mice/time point). **p ⬍ 0.01, relative to baseline (one-way ANOVA with Bonferroni’s post hoc test). B, CFA-induced thermal measurements were performed using NGF
hyperalgesia was compared between three groups of C57BL/6J wild-type mice. The first group received daily administration of (MD Millipore) and PGE2 (Cayman Chemical)
vehicle control (black circles; n ⫽ 8), the second group received daily administration of the C5aR1 antagonist PMX53 (red triangles; ELISA kits, respectively, according to the
n ⫽ 7), and the third group received a single injection of PMX53 (1 h before testing) on day 3 after CFA injection (green squares; manufacturer’s recommendations. Multiplex
n ⫽ 8). *p ⬍ 0.05, relative to control (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). Greenandredasterisks ELISA was performed using the Stanford Human
indicate PMX53 (daily) and PMX53 (day 3) mouse groups, respectively. C, D, CFA-induced mechanical hyperalgesia is significantly reduced Immune Monitoring Core 26-plex (Stanford
after administration of PMX53. CFA was injected into the plantar surface of wild-type (C57BL/6J) mice; and then 1 d after CFA injection, University, Palo Alto, CA) and tested for the
eitherasalinecontrol(n⫽10)orPMX53(n⫽11)wasadministered.AfterCFA,day1waschosenbasedontheC5aR1KOfindings(Fig.1B) following cytokines and growth factors:
asthetimeatwhichCFA-inducedmechanicalsensitizationwasmostsignificantlyreducedinC5aR1KOcomparedwithwild-typemice.Paw eotaxin (CCL11), granulocyte colony-stimulating
withdrawalthresholdsweremeasuredeitherbeforeor1and3hafterPMX53injection.C,HighlightedareaisreplottedforclarityinDusing factor (G-CSF), granulocyte-monocyte colonyan extended time scale. *p ⬍ 0.05, relative to control (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). E, Thermal stimulating factor (GM-CSF), interferon-␥
hyperalgesia induced by CFA injection was reduced by PMX53 administration 3 d after CFA injection in wild-type (BALB/C; n ⫽ 9) but not (IFN-␥), IFN-␥-inducible protein 10 (IP-10/
C5aR1 KO (n ⫽ 9) mice. Thermal sensitivity was tested on day 3 after CFA immediately before (time ⫽ 0 h) and 1 h after PMX administra- CXCL10), interleukins IL-1␣, IL-1␤, IL-2, IL-3,
tion. F, Mechanical hyperalgesia induced by CFA injection was reduced by PMX53 administration 1 d after CFA injection in wild-type IL-4, IL-5, IL-6, IL-10, IL-12-P40, IL-12-P70, IL(BALB/C; n ⫽ 8) but not C5aR1 KO (n ⫽ 9) mice. Mechanical sensitivity was tested on day 1 after CFA immediately prior (time ⫽ 0 h) and 13, IL-17, and IL-23, keratinocyte-derived
1 and 3 h after PMX administration. ***p ⬍ 0.001, relative to baseline (time ⫽ 0 h; E, F) (two-way repeated-measures ANOVA with chemokine (KC/CXCL1), monocyte chemoattractant protein 1 (MCP-1/CCL2), monocyte
Bonferroni’s post hoc test).
chemoattractant protein 3 (MCP-3/CCL7),
macrophage inflammatory protein 1␣ (MIP1␣/CCL3), RANTES (CCL5), tumor necrosis
of the IITC Plantar Analgesia Meter. Baseline latency was determined
factor ␣ (TNF-␣), transforming growth factor ␤ (TGF-␤), and vascular
shortly (15–30 min) before drug administration, by averaging the results
endothelial growth factor (VEGF).
of three tests separated by a 5 min interval. For the von Frey testing,
For the experiments involving C5a measurements, 20 l CFA (1 mg/
mechanical sensitivity was assayed by calculating the 50% response
ml) was administered subcutaneously into the hindpaw as described
threshold to 5 presentations each of 0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, and
above. Mice (C57BL/6J) were killed by cervical dislocation under isoflu2 g von Frey filaments (Stoelting). After baseline measurements were
rane anesthesia at various time points after injection: 1, 3, and 8 d. Basetaken, either 500 ng recombinant mouse C5a in 10 l PBS, 10 ng NGF in
line measurements were performed using naive C57BL/6J mice. The
10 l PBS, or 20 l of Complete Freund’s adjuvant (CFA) suspension
skin was removed as described above and then frozen at ⫺80°C until
(1 mg/ml) was injected into the plantar surface of the hindpaw using
used for a C5a ELISA (R&D Systems) performed according to the
a 33-gauge needle (26 gauge in the case of CFA) coupled to a Hamilmanufacturer’s recommendations.
ton syringe. NGF neutralizing antibody, IgG (control), or GNF-5837
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Immunohistochemistry. Immunohistochemical staining and analysis were performed as
previously described (Loo et al., 2012; Shepherd and Mohapatra, 2012; Mickle et al.,
2015b). In brief, adult male mice were killed
and immediately underwent intracardiac perfusion with 4% PFA in 0.1 M phosphate buffer
(PB). After fixation, 3 mm plantar punches
were taken using a Harris Micro-Punch (Ted
Pella), postfixed for 16 h in 4% PFA with 5%
picric acid, incubated for 16 h in decalcification
buffer (10% EDTA, 0.07% glycerol, and 15%
sucrose in 0.1 M PB), 16 h in cryoprotectant
(30% sucrose in 0.1 M PB), embedded in Optimal Cutting Temperature (Sakura Finetek),
frozen, and sectioned into 40 m sections using a cooled cryostat (CM3050 S; Leica Microsystems). The tissue slices were blocked for 1 h
with blocking buffer containing either 10%
goat (Sigma) or donkey serum (The Jackson
Laboratory) and 0.3% Triton X-100 in 0.1 M
PB. Tissue slices were then incubated with primary antibodies diluted in blocking buffer for
24 h, washed 3 times with blocking buffer, and
then incubated with secondary antibodies for Figure 3. C5a-induced thermal hyperalgesia depends on C5aR1 and TRPV1. A, Thermal sensitivity was measured before (base2 h. After staining, the sections were mounted line time ⫽ 0 h) and at various times after injection of 0 (Sham), 10, 100, 500, or 2500 ng C5a (in 10 l) into the plantar surface of
on microscope slides with ProLong Gold the hindpaw of wild-type (C57BL/6J) mice (n ⫽ 4 or 5 mice per dose). B, Thermal sensitivity (paw withdrawal latency) was
(Invitrogen). We used the following primary measured before (baseline time ⫽ 0 h) and at various times after injection of C5a (500 ng in 10 l) into the plantar surface of the
antibodies: rat anti-C5aR1 (1:500; clone hindpaw of either wild-type (BALB/C; black circles; n ⫽ 7) or C5aR1 KO mice (red squares; n ⫽ 6). ***p ⬍ 0.001, relative to
10/92, catalog #MCA2456GA AbD Serotec), wild-type mice (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). C, D, Thermal sensitivity was measured
rat anti-F4/80 (1:500; clone A3-1; catalog before (baseline time ⫽ 0 h) and after injection of C5a either alone (500 ng; black circles and red squares) or in combination with
#MCA497GA; AbD Serotec), rabbit anti-IBA1 the TRPV1 antagonist AMG9810 (67 ng AMG9810 ⫹ 500 ng C5a; green triangles) into the plantar surface of a mouse hindpaw.
(1:500; catalog #019-19741; Wako Chemicals), Three groups of mice were examined: (1) wild-type mice (C57BL/6J) injected with C5a alone (black circles; n ⫽ 18); (2) wild-type
and guinea pig anti-TRPV1 C terminus (1: mice injected with the combination of C5a and AMG9810 (green triangles; n ⫽ 11); and (3) TRPV1 KO mice injected with C5a (red
1000; catalog #GP14100; Neuromics). All of squares; n ⫽ 8). D, Data are from the same experiments as in C but are normalized to baseline values for each animal. *p ⬍ 0.05,
these primary antibodies were described previ- relative to wild-type mice treated with C5a (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
ously (Hume et al., 1984; Imai et al., 1996; Guo **p ⬍ 0.01, relative to wild-type mice treated with C5a (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
et al., 1999; Sasmono et al., 2003; Soruri et al., ***p ⬍ 0.001, relative to wild-type mice treated with C5a (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
2003; Tschernig et al., 2007; Brennan et al., Green and red asterisks indicate wild-type/C5a⫹AMG and TRPV1KO/C5a mouse groups, respectively.
2015). AlexaFluor-488- and AlexaFluor-555density. Cells were incubated for 24 – 48 h before being used for calcium
conjugated goat or donkey secondary antibodies (Invitrogen) were used
imaging, immunocytochemistry or RT-PCR.
at a 1:1000 dilution. Images were captured using an Olympus BX61WI
Transfection of primary macrophages. Macrophages were isolated as
microscope equipped with the Fluoview 300 laser-scanning confocal imdescribed and plated on 100 mm culture dishes for 24 h. The macroaging system and either a 20⫻ objective (NA 0.75; Olympus) or a 60⫻
phages were then transfected using a Nucleofector Kit for Mouse Macoil-immersion objective (NA 1.40; Olympus). For quantification, IBA1rophages (catalog #VAPA-1009; Lonza) according to the manufacturer’s
stained macrophages were imaged by an investigator blinded to the treatprotocol. Macrophages are a notoriously difficult to transfect cell type;
ment conditions, and quantified using ImageJ software.
and after experimentation with different transfection techniques, we
Primary macrophage culture. Primary macrophages were isolated and
found that an Amaxa/Lonza nucleofection-based protocol provided
cultured as described by Ray and Dittel (2010). Fluid thioglycolate me⬃35% transfection efficiency. This was substantially better than the redium (4%) (BD Biosciences) was prepared by boiling until the thioglysults obtained using Lipofectamine 2000 (ThermoFisher) and magnetocolate was dissolved, and then autoclaved. After cooling, 3 ml of 4%
fection (Oz Biosciences), which yielded ⬍2% efficiency after extensive
thioglycolate was injected into the peritoneal cavity of C57BL/6J,
optimization (data not shown).
BALB/C, PLC␤2 KO, or C5aR1 KO mice. Six days after injection, the
For our transfection protocol, cultured primary macrophages were
mice were killed, and 5 ml of ice-cold PBS with 3% FBS was injected into
briefly washed with PBS, placed in 3 ml 0.05% trypsin for 30 min, gently
the peritoneal cavity with a 27G needle. The peritoneum was gently masscraped, diluted with 7 ml growth media, and counted. Cells were made
saged for 1 min to loosen and detach cells. The fluid was then removed by
into aliquots of 1.0 ⫻ 10 6 cells/transfection and spun down at 200 ⫻ g for
inserting a 25G needle into the peritoneum and slowly drawing out the
10 min. The cells were resuspended in 100 l Nucleofector solution ⫹
fluid. Another 5 ml of PBS ⫹ 3% FBS was then injected, the peritoneum
supplement ⫹ 3 g of plasmid DNA, transferred to an electroporation
was again massaged, and the fluid was removed in the same manner. The
cuvette, and then transfected using the Y-001 program of the Amaxa
cells were then spun down at 1500 RPM for 8 min, the supernatant was
Nucelofector II device (Lonza). Culture media (600 l) was added to the
removed, and the cells were resuspended in Complete Macrophage Mecuvette and then transferred to a microcentrifuge tube with 650 l of
dium (ScienCell Research Laboratories). The cells were then plated at 6
media. Cells were then plated on six poly-D-lysine-coated glass coverslips
different dilutions on poly-D-lysine (Sigma)-coated glass coverslips using
using 8 mm cloning cylinders (⬃210 l per cylinder) and were removed
8 mm cloning cylinders and kept in a 5% CO2 incubator at 37°C for 1 h
before adding additional growth media. The cloning cylinders were reafter 1 h after adding 3 ml of growth media to the 6-well dish. For each
moved, the cells were washed with growth media to remove nonadherent
transfection (⬃10 6 cells/transfection), we used either 1 g of each
cells, and then the appropriate cell density was determined by microsshRNA construct plus 1 g of pmaxGFP (Lonza) or 2 g pLKO.1 empty
copy as yield of macrophages versus nonadherent cells varies. A density
vector DNA (GE Dharmacon) plus 1 g of pmaxGFP. A set of shRNA
of ⬃75% confluency was chosen, and remaining cells were plated at that
plasmids (in pLKO.1 vector) targeting mouse PLC␤3 were purchased
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nm bandpass) using the Polychrome V
monochromator (T.I.L.L. Photonics) and a
20⫻ objective (NA 0.75; Olympus). Emitted
fluorescence was collected at 510 nm (84 nm
bandpass) using an IMAGO CCD camera
(T.I.L.L. Photonics). Pairs of 340/380 nm images were sampled at 1 Hz. The fluorescence
ratio (r ⫽ F340/F380) was converted to [Ca 2⫹]i
according to the formula [Ca 2⫹]i ⫽ Kd␤(R ⫺
Rmin)/(Rmax ⫺ R) (Grynkiewicz et al., 1985).
The dissociation constant (Kd) used for fura-2
was 275 nM (Shuttleworth and Thompson,
1991). Rmin, Rmax, and ␤ were determined by
applying 10 M ionomycin in either Ca 2⫹-free
buffer (with 1 mM EGTA) or HH buffer
(1.3 mM Ca 2⫹). Calibration constants were as
follows: Rmin ⫽ 0.22, Rmax ⫽ 3.07, and ␤ ⫽
6.05. Fluorescence was corrected for background, as determined by an area that did not
contain a cell. Data were processed using TILLvisION (T.I.L.L. Photonics) and the GraphPad
Prism 6 software, and are presented as
mean ⫾ SEM.
Immunocytochemistry. Cells were washed
with PBS and then fixed with 4% PFA for
15–20 min at room temperature. Cells were
then washed 3 times with PBS for 5 min/wash,
incubated for 30 min in blocking buffer (5%
goat serum and 0.1% Triton X-100 in PBS),
and incubated with rat anti-C5aR1 (1:500;
clone 10/92, AbD Serotec) and rabbit antiIBA1 (1:500; Wako Chemicals). The cells were
washed 3 times with blocking buffer and then
incubated with AlexaFluor-488 goat anti-rat
and AlexaFluor-555 goat anti-rabbit secondary
antibodies (1:1000; Invitrogen) in blocking
buffer at room temperature and in darkness for
30 min. Cells were washed with PBS 3 times
and then mounted on a slide using anti-fade
reagent Fluoromount-G (Southern Biotechnology). Images were captured using an OlymFigure 4. C5aR1 in the skin is expressed primarily in macrophages. Immunohistochemical analysis was performed in skin pus BX61WI microscope equipped with the
sections from the mouse hindpaw as described in Materials and Methods, and the images were obtained using either a 20⫻ (A, B; Fluoview 300 laser-scanning confocal imaging
NA ⫽ 0.75; Olympus) or a 60⫻ (C, D; oil-immersion, NA ⫽ 1.40; Olympus) objective. A, B, Expression of C5aR1 (red) and IBA1 system and a 60⫻ oil-immersion objective
(green; a molecular marker of macrophages) in skin from wild-type (A) or C5aR1 KO (B) mice. C, Expression of IBA1 (green) and (NA 1.40, Olympus) as previously described
another macrophage marker, F4/80 (red), in the skin. D, Expression of TRPV1 (green; primary afferent fibers) and IBA1 (red; (Schnizler et al., 2008).
Western blotting. Cells were collected in homacrophages) in the skin. Left, Single Z-plane. Right, Z-stack composite image (⌬Z ⫽ 15 m; Z-step ⫽ 0.25 m).
mogenization buffer (100 mM NaCl, 50 mM
Tris/HCl, 0.1 mM EDTA, and 1% Triton
from GE Dharmacon (catalog #RMM4534-EG18797; developed by the
X-100) containing a protease inhibitor mixture (Sigma, 1:50) and a phosBroad Institute’s RNAi Consortium/TRC). Using the NIH-3T3 cells, we
phatase inhibitor (Sigma, 1:100) and homogenized with a 25-gauge neeidentified two shRNA plasmids that produced the highest knockdown
dle. Cell lysates were then diluted with Laemmli reducing buffer and
(see Fig. 6F ), shRNA#1 (ID: TRCN0000076916; 5⬘-TTTCCAAGGGA
heated at 95°C for 5 min before loading 20 g of protein/sample into an
AACTCATCAG-3⬘) and shRNA #2 (ID: TRCN0000076914; 5⬘-TTT
8% SDS-polyacrylamide gel. Proteins in SDS-PAGE gels were transferred
GATGAACTTACTCCCGCG-3⬘). Ca 2⫹ imaging was performed 48 h
to nitrocellulose membranes (Bio-Rad) using the transfer buffer (1.5 g
after transfection. Transfected cells were identified by maxGFP fluoresTris-HCl, 7.2 g glycine, and 150 ml MeOH dissolved in 1000 ml H2O).
cence. The described approach resulted in ⬃95% cotransfection as veriThen, the membrane was incubated with a blocking solution composed
fied by cotransfecting macrophages with mCherry and maxGFP and
of 5% skim milk in TBS (20 mM Tris-HCl, pH 7.5, and 150 mM NaCl) for
quantifying cells that coexpress both fluorescent proteins (data not
1 h, washed briefly with TBS, and then incubated with primary antibodshown).
ies for 4 h. The following primary antibodies were used: rabbit antiCalcium imaging. The standard extracellular HEPES-buffered HBSS
PLC␤2 (1:500; catalog #sc-206; Santa Cruz Biotechnology) and rabbit
(HH buffer) contained the following (in mm): 140 NaCl, 5 KCl, 1.3
anti-PLC␤3 (1:500; catalog #sc-403 Santa Cruz Biotechnology). Both
CaCl2, 0.4 MgSO4, 0.5 MgCl2, 0.4 KH2PO4, 0.6 NaHPO4, 3 NaHCO3, 10
antibodies were extensively described and validated (Ali et al., 1997;
glucose, and 10 HEPES, pH 7.35 with NaOH (310 mOsm/kg with suTordjmann et al., 1998; Runnels et al., 2002; Galeotti et al., 2006). GRP75
crose). Primary macrophages were incubated for 25 min with 2 M of
was used as a loading control and probed with a monoclonal anti-GRP75
fura-2 AM (Invitrogen) at room temperature (22°C). Cells were placed in
antibody (1:2000; clone N52A/42; Neuromab). The membranes were
a flow-through chamber mounted on the stage of an inverted IX-71
then washed with TBS and incubated either with HRP-conjugated goat
microscope (Olympus) and washed for 10 min with HH buffer before the
anti-rabbit antibodies (1:1000; catalog #A0545, Sigma) or with HRPexperiment. C5a and other drugs were applied by continuous bath suconjugated goat anti-mouse antibodies (1:2000; catalog #48-146-H; Anperfusion. Fluorescence was alternately excited at 340 and 380 nm (12
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Figure 5. C5a produces a strong [Ca 2⫹]i response in macrophages. A, Immunostaining in mouse primary macrophages shows coexpression of IBA1 (red) and C5aR1 (green). B, Bright-field image
and three images color-coded for [Ca 2⫹]i represent the same field of mouse primary macrophages loaded with fura-2. The color-coded images show the distribution of [Ca 2⫹]i in macrophages at
rest, and at 5 and 15 s after 100 nM C5a was applied. C, Concentration dependence of [Ca 2⫹]i responses to C5a in macrophages. [Ca 2⫹]i recording was performed simultaneously from several
individual macrophages (each cell represented by a different color) in response to 1, 10, or 100 nM C5a applied for 1 min. The [Ca 2⫹]i responses to each concentration of C5a were recorded using
different coverslips with macrophages. D–G, Representative [Ca 2⫹]i recordings demonstrating the effects of Ca 2⫹-free extracellular buffer (supplied with 0.1 mM EGTA) (D), SERCA inhibitor
cyclopiazonic acid (10 M; E), structurally distinct SERCA inhibitor thapsigargin (1 M; F ), and G␤␥ inhibitor gallein (10 M; G) on [Ca 2⫹]i elevations induced by 10 nM C5a (1 min) in macrophages.
H, Bar graph summarizes the effects of Ca 2⫹-free extracellular solution, cyclopiazonic acid, thapsigargin, galleon, and C5aR1 KO on the amplitude of [Ca 2⫹]i responses in macrophages evoked by
C5a application (10 nM, 1 min). ***p ⬍ 0.001, relative to control (one-way ANOVA with Bonferroni’s post hoc test) (n ⫽ 54 –170 cells). Primary macrophages for immunostaining and all of the
[Ca 2⫹]i recordings were obtained from wild-type C57BL/6J mice, except those obtained from C5aR1 KO mice (H, green bar; BALB/C background). The amplitude of C5a-induced (10 nM, 1 min)
[Ca 2⫹]i elevations in macrophages from wild-type BALB/C mice (799 ⫾ 62 nM; n ⫽ 25; data not shown) was similar to that in macrophages from wild-type C57BL/6J mice (891 ⫾ 29 nM; n ⫽ 170;
p ⫽ 0.21, unpaired Student’s t test).

tibodies). Membranes were then washed and developed with ECL⫹ HRP
detection kit (GE Healthcare). All the experiments were repeated 3–5 times.
RT-PCR. Total RNA was isolated from primary mouse macrophages
24 – 48 h after plating or from mouse (C57BL/6J) hippocampi using the
RNase easy Plus Mini Kit (QIAGEN) with added on-column DNase-I digestion according to the manufacturer’s recommendations. The purified RNA
was then reverse transcribed and amplified using the one-step RT-PCR kit
(QIAGEN). The following primer sets were used: GAPDH forward: 5⬘ACCACAGTCCATGCCATCAC-3⬘; GAPDH reverse: 5⬘-CACCACCCT
GTTGCTGTAGCC-3⬘; NGF forward: 5⬘-ACAGGCAGAACCGTA
CACAG-3⬘; NGF reverse: 5⬘-TGACGAAGGTGTGAGTCGTG-3⬘; C5aR1
forward: 5⬘-CAGGGACCTTCAGGCATCCATT-3⬘; C5aR1 reverse: 5⬘TTTGAGCGTCTTGGTGGAGC-3⬘. RT-PCRs were performed using a Biometra T3 thermocycler. The No RT control reaction did not have a reverse
transcription step and was used as a control for contamination with genomic

DNA. The amplified PCR products were separated by electrophoresis on a
2% agarose gel and were detected using ethidium bromide.
Reagents. Recombinant mouse C5a, GNF-5837, AMG9810, U73122,
U73343, o-3M3FBS, m-3M3FBS, thapsigargin, cyclopiazonic acid, and
gallein were purchased from R&D Systems/Tocris Bioscience. CFA was
purchased from Sigma; fura-2 AM was obtained from Invitrogen. NGF
neutralizing antibody and IgG control were purchased from Ex␣ Biologicals (catalog #L148M and 0G11, respectively). NGF was from AbD Serotec, and AP20187 (B/B homodimerizer) was from Takara/Clontech.
PMX53 (AcF-[OPdChaWR]acetate salt) was synthesized as reported
previously (March et al., 2004), purified by reversed-phase highperformance liquid chromatography, and fully characterized by mass
spectrometry.
Statistical analysis. Data are expressed as mean ⫾ SEM. The following
tests were used for analyzing the data: unpaired Student’s t (comparison
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Figure 6. C5a-induced [Ca 2⫹]i elevation in macrophages depends on PLC signaling. A–E, Representative [Ca 2⫹]i recordings demonstrate the effects of PLC inhibitor U73122 (1 M; A), inactive
analog of U73122, U73343 (1 M; B), PLC activator, m-3M3FBS (25 M; C), its inactive variant, o-3M3FBS (25 M; D), and PLC␤2 KO (E) on C5a-induced Ca 2⫹ mobilization in macrophages. F,
Western blot analysis was used to examine expression of PLC␤3 in wild-type macrophages (lane 5) and NIH-3T3 cells (lanes 1– 4) transfected with shRNA against PLC␤3 (lanes 1 and 2), PLC␤3
(overexpression [OE]; lane 3), or empty vector (pLKO.1; lane 4). GRP75 was used as a loading control. G, Western blot analysis shows expression of PLC␤2 in wild-type (lane 1), but not in PLC␤2 KO
(lane 2) mice (GRP75 as a loading control). H, I, Representative [Ca 2⫹]i recordings were obtained from PLC␤2 KO macrophages transfected either with empty vector (pLKO.1) ⫹ maxGFP (n ⫽ 16;
H ) or PLC␤3 shRNA#1 ⫹ #2 ⫹ maxGFP (n ⫽ 13; I ). Transfected macrophages were identified by maxGFP fluorescence. J, Bar graph summarizes the effects of U73122, U73343,
m-3M3FBS, o-3M3FBS, PLC␤2 KO, empty vector, and PLC␤3 shRNAs on the amplitude of C5a-induced [Ca 2⫹]i elevations in macrophages. **p ⬍ 0.01, ***p ⬍ 0.001, relative to control
(wild-type macrophages, n ⫽ 170; replotted from Fig. 5H ) (one-way ANOVA with Bonferroni’s post hoc test). ##p ⬍ 0.01, relative to naive PLC␤2 KO macrophages (n ⫽ 13–134 cells)
(one-way ANOVA with Bonferroni’s post hoc test).

of 2 groups), one-way ANOVA with Bonferroni’s post hoc test (comparison of ⬎2 groups), or two-way repeated-measures ANOVA with Bonferroni’s post hoc test (time course with comparison of 2 or more groups).
A value of p ⬍ 0.05 was considered statistically significant in all cases.
Statistical analyses were performed using the GraphPad Prism 6 software.

Results
C5aR1 significantly contributes to thermal hyperalgesia in the
CFA model of inflammatory pain
We first examined the role of C5aR1 in the development and
maintenance of inflammatory pain induced by CFA (Stein et al.,
1988; Gregory et al., 2013). Intraplantar injection of CFA in wildtype mice produced long-lasting thermal (Fig. 1A) and mechanical (Fig. 1B) hypersensitivity. CFA-induced thermal hyperalgesia
was significantly reduced in C5aR1 KO mice, showing recovery to
baseline levels by day 3 after CFA injection (Fig. 1A). C5aR1 KO
mice also exhibited a significant reduction in mechanical sensitization (Fig. 1B). Assessment of C5a levels by ELISA revealed a
significant and prolonged increase at the site of CFA-induced

inflammation, with full recovery by day 8 after injection
(Fig. 2A). We also examined the effects of the C5aR1 antagonist
PMX53 on CFA-induced thermal hyperalgesia (Woodruff et al.,
2002, 2006; Proctor et al., 2006). As shown in Figure 2B, daily
administration of PMX53 to wild-type animals markedly diminished thermal hyperalgesia (green squares) compared with
control (vehicle-treated; black circles) animals. Furthermore,
acute treatment with PMX53 on day 3 after CFA injection
rapidly and reversibly reduced thermal hyperalgesia (Fig. 2B,
red triangles). Similarly, PMX53 administration 1 d after CFA
injection significantly reduced mechanical hyperalgesia (Fig.
2C,D). In contrast, administration of PMX53 in C5aR1 KO
mice did not affect CFA-induced thermal and mechanical hyperalgesia, which is consistent with the selectivity of PMX53
for C5aR1 under our experimental conditions (Fig. 2 E, F ).
These data suggest that C5aR1 plays a critical role in the development and maintenance of thermal and mechanical hyperalgesia during inflammation.
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C5a-induced thermal hyperalgesia is
mediated by TRPV1
Next, we aimed to identify mechanisms
that are responsible for C5aR1-dependent
thermal hyperalgesia. In these experiments, thermal hyperalgesia was produced by intraplantar injection of C5a
(Fig. 3) as previously described (Jang et
al., 2010, 2011). We first examined a dose
dependence of C5a with intraplantar injection of 0 (sham), 10, 100, 500, or 2500
ng of C5a in wild-type mice (Fig. 3A). As
500 ng showed no significant difference
from 2500 ng and lasted much longer than
100 ng, 500 ng was chosen as an optimal
dose for further experiments. Two receptors for C5a have been identified, C5aR1
and C5aR2 (Monk et al., 2007; Klos et al.,
2013; Kemper et al., 2014). We found that
C5a-induced thermal hyperalgesia was
absent in C5aR1 KO mice (Fig. 3B), suggesting that C5aR1 is responsible for the
effects of C5a injection. This is consistent
with a previous report that the C5aR1 antagonist PMX53 blocked C5a-induced Figure 7. Macrophage depletion abolishes C5a-induced thermal hyperalgesia. A, B, IBA1 staining of plantar skin sections
thermal hyperalgesia (Jang et al., 2011).
obtained from MAFIA mice treated with vehicle (A) or AP20187 (B) for 5 d. C, Quantification of IBA1 immunoreactivity in plantar
Next, we sought to identify a nocicep- skin of the hindpaw after 5 d of treatment with vehicle or AP20187. ***p ⬍ 0.001 (unpaired Student’s t test). D, Paw withdrawal
tive ion channel or receptor that could latencies after injection of C5a into the plantar surface of MAFIA mice treated with vehicle (black squares; n ⫽ 5) or AP20187 (red
mediate the hyperalgesic effect of C5a. circles; n ⫽ 11). ***p ⬍ 0.001, relative to vehicle (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
TRPV1 was chosen as a likely candidate
that innervate the skin (Fig. 4D), consistent with a potential role
given that it is a polymodal nonselective cation channel that is
of these cells in activating nociceptive signaling.
expressed in primary nociceptors and is activated by noxious
We also examined C5aR1 expression in macrophages at a
heat, acidic pH, and lipid-derived endovanilloids. The channel is
functional level. Intracellular Ca 2⫹ signals control many aspects
also critical for development of inflammatory thermal hyperalgeof macrophage activation and function, including migration and
sia (Caterina et al., 1997; Caterina et al., 2000; Davis et al., 2000;
cytokine expression and secretion (Onozaki et al., 1983; UnderBhave and Gereau, 2004; Immke and Gavva, 2006; Patapoutian et
wood and Riches, 1992; Yamamoto et al., 2008; Fric et al., 2012;
al., 2009; Mickle et al., 2015a). We thus tested its role in the C5a
Desai and Leitinger, 2014). Therefore, we used Ca 2⫹ imaging in
pronociceptive effect using TRPV1 KO mice (Caterina et al.,
primary mouse macrophages to test their response to C5a. Like
2000). We observed a small increase in baseline paw withdrawal
macrophages in the skin, the cultured primary macrophages
latency in TRPV1 KO mice (Fig. 3C) consistent with previous
prominently expressed C5aR1 (Fig. 5A). We found that brief
reports of mild deficit in heat sensitivity in these animals (Caapplication of C5a (1–100 nM, 1 min) produced a doseterina et al., 2000; Vardanyan et al., 2009). More importantly,
dependent increase in the intracellular Ca 2⫹ concentration
C5a-induced thermal hyperalgesia was nearly abolished in the
([Ca 2⫹]i) in all macrophages (Fig. 5 B, C). This C5a-evoked eleTRPV1 KO mice (Fig. 3C,D). Furthermore, coadministration of
vation of [Ca 2⫹]i was absent in macrophages obtained from
the TRPV1 antagonist AMG9810 blocked the pronociceptive efC5aR1 KO mice, indicating that the effect was mediated by
fect of C5a in wild-type animals (Fig. 3C,D). These data indicate
C5aR1. Removing extracellular Ca 2⫹ reduced the amplitude
that TRPV1 is a critical effector of the C5a-induced signaling that
of C5a-induced [Ca 2⫹]i response by ⬃30% (Fig. 5D). Depletion
leads to thermal hyperalgesia.
of intracellular Ca 2⫹ stores using the inhibitors of the sarcoendoplasmic reticulum Ca 2⫹-ATPase (SERCA), cyclopiazonic acid
Macrophages are required for C5a-induced
(10 M), or thapsigargin (Tg; 1 M), produced a much stronger
thermal hyperalgesia
effect, diminishing the [Ca 2⫹]i response by ⬃80% and ⬃95%,
To identify the cell type(s) that mediates the effect of C5a, we
respectively (Fig. 5 D, E). These findings suggest that intracellular
examined C5aR1 expression in the glabrous skin of the mouse
Ca 2⫹ stores are a major source of C5a-induced Ca 2⫹ mobilizahindpaw. Using a C5aR1-specific antibody, we found a distinct
tion in macrophages.
immunoreactivity in skin sections from wild-type mice, but not
C5aR1 is a G␣i-coupled receptor whose activation triggers
in those from C5aR1 KO mice (Fig. 4 A, B). The majority of the
multiple signaling events, including G␤␥-dependent activation
cells that were immunoreactive for C5aR1 also expressed the
of PLC␤ (Monk et al., 2007; Klos et al., 2013). We focused on the
macrophage marker IBA1 (Imai et al., 1996; Vega-Avelaira et al.,
G␤␥-PLC signaling pathway because it is well known to lead to
2009; Kwon et al., 2013). The IBA1-positive cells expressed anthe synthesis of inositol 1,4,5-trisphosphate (IP3) and IP3other macrophage marker, F4/80, confirming that the described
induced release of Ca 2⫹ from intracellular stores in various cell
cells are macrophages (Davies et al., 2013) (Fig. 4C). These mactypes (Berridge et al., 2003; Clapham, 2007). We found that the
rophages were found in close proximity to TRPV1-positive fibers
C5a-induced [Ca 2⫹]i increase in macrophages was significantly
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that the C5a-induced [Ca 2⫹]i response in
these cells was reduced by ⬃50% compared with that in wild-type macrophages
(Fig. 6 E, J ). An additional shRNA-based
knockdown of PLC␤3 in PLC␤2 KO macrophages virtually eliminated (⬃94% reduction compared with wild-type
macrophages) the C5a-induced [Ca 2⫹]i
elevation in macrophages (Fig. 6 I, J ). Collectively, these data suggest that C5a produces a strong [Ca 2⫹]i response in
macrophages by triggering G␤␥- and
PLC␤-dependent Ca 2⫹ release from intracellular (most likely IP3-sensitive)
Ca 2⫹ stores, as well as Ca 2⫹ entry via the
plasma membrane.
Next, we tested the role of macrophages in C5a-induced thermal hyperalgesia by using the MAFIA mouse, a
transgenic model of drug-inducible macrophage ablation (Burnett et al., 2004).
These mice express a suicide gene that
leads to c-Fas ligand-mediated apoptosis
and is controlled by the macrophage/
monocyte-specific promoter c-fms (Yue et
al., 1993; Sasmono et al., 2003; Burnett et
al., 2004). Daily administration of the
transgene activator, AP20187, to MAFIA
mice for 5 d decreased macrophage staining (IBA1) in the plantar skin by 85% relative to vehicle-treated controls (Fig.
Figure 8. Intraplantar injection of C5a elevates numerous inflammatory mediators. Time-dependent changes in skin levels of 7A–C). In vehicle-treated MAFIA mice,
selected inflammatory factors are shown before (time ⫽ 0 h) and at various time points after C5a injection for IL-6 (A), TNF-␣ (B), intraplantar injection of C5a elicited a
PGE2 (C), NGF (D), MCP-1/CCL2 (E), and MIP-1␣/CCL3 (F ). The complete dataset is shown in Table 1. Horizontal dotted lines rapid and strong thermal hyperalgesia
indicate the baseline levels for each mediator. Vertical dotted lines indicate the 0.5 h time point after C5a injection, at which time (Fig. 7D, black circles) similar to that obthermal hyperalgesia became significant (Figs. 3, 7). Among these mediators, NGF showed the fastest (peak at 0.5 h) increase in served in wild-type mice (Fig. 3). In
response to C5a injection. *p ⬍ 0.05, relative to baseline (one-way ANOVA with Bonferroni’s post hoc test). **p ⬍ 0.01, relative contrast, intraplantar injection of C5a
to baseline (one-way ANOVA with Bonferroni’s post hoc test). ***p ⬍ 0.001, relative to baseline (one-way ANOVA with Bonferproduced no changes in thermal sensitivroni’s post hoc test). n ⫽ 4 independent experiments/time point.
ity in the macrophage-depleted MAFIA
mice (Fig. 7D, red squares). Thus, resident
macrophages (and potentially monocytes) are required for the
diminished by application of either the G␤␥ inhibitor gallein (10
M; Fig. 5G) (Lehmann et al., 2008) or the PLC inhibitor U73122
development of C5a-induced thermal hyperalgesia.
(1 M; Fig. 6A) (Bleasdale et al., 1990). The inactive analog of
U73122, U73343, had no effect on C5a-induced [Ca 2⫹]i elevaNGF plays a critical role in C5a-induced thermal hyperalgesia
tions (1 M; Fig. 6B). Similar to C5a, a selective PLC activator,
Based on the data described above, a plausible scenario is that
m-3M3FBS (25 M; Fig. 6C), but not its inactive analog
subcutaneously administered C5a acts on macrophages in the
o-3M3FBS (25 M; Fig. 6D), produced [Ca 2⫹]i increase in macskin to trigger macrophage-to-nociceptor signaling that ultirophages that was blocked by depleting intracellular Ca 2⫹ stores
mately leads to TRPV1 sensitization and the development of
with 1 M Tg. Indeed, under control conditions, the amplitude of
thermal hyperalgesia. To identify signaling molecules that might
m-3M3FBS-elicited [Ca 2⫹]i elevation was 1043 ⫾ 90 nM (n ⫽
mediate this cross-cellular communication, we examined how
45), whereas after a pretreatment with Tg it was diminished to
intraplantar injection of C5a alters the expression profiles of cy137 ⫾ 44 nM (n ⫽ 22; p ⬍ 0.001, unpaired Student’s t test).
tokines and other inflammatory mediators in the skin at the site
Furthermore, treatment with m-3M3FBS, but not with
of injection, using a mouse multiplex cytokine analysis kit and
o-3M3FBS, prevented a further [Ca 2⫹]i elevation upon C5a apELISA. We found that C5a injection induced a time-dependent
plication (Fig. 6C,D), suggesting that C5a and the PLC activator
upregulation of numerous cytokines, as well as NGF and PGE2
m-3M3FBS use a common signaling pathway leading to [Ca 2⫹]i
(Fig. 8; Table 1). Given our finding that TRPV1 plays a key role in
increase in macrophages.
C5a-induced thermal hyperalgesia, we focused our attention on
Previous studies have reported that the PLC isoforms ␤2 and
inflammatory mediators that are known to sensitize this receptor,
␤3 are primarily responsible for C5a-induced signaling in macsuch as PGE2, NGF, IL-6, TNF-␣, MCP-1 (also known as CCL2),
and MIP-1␣ (also known as CCL3) (Lopshire and Nicol, 1998;
rophages (Wang et al., 2008; Rebres et al., 2011). Using the
Zhang et al., 2005a, b; White et al., 2007; Constantin et al., 2008;
PLC␤2- and PLC␤3-specific antibodies, we also found that both
PLC isoforms are expressed in macrophages (Fig. 6 F, G). ExamJung et al., 2008; Khan et al., 2008; Schnizler et al., 2008; Andination of cultured macrophages from PLC␤2 KO mice showed
ratsch et al., 2009; Russell et al., 2009). Among these mediators,
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Table 1. C5a-induced changes in the levels of inflammatory mediators in the skina
Analyte

Controlb

0.5 h

1h

2h

3h

24 h

Eotaxin/CCL11
G-CSF
GM-CSF
IFN-␥
IL-1␣
IL-1␤
IL-2
IL-3
IL-4
IL-5
IL-6
IL-10
IL-12-P40
IL-12-P70
IL-13
IL-17
IL-23
IP-10/CXCL10
KC/CXCL1
MCP-1/CCL2
MCP-3/CCL7
MIP-1␣/CCL3
NGF
PGE2
RANTES/CCL5
TGF-␤
TNF-␣
VEGF

250 ⫾ 21
2.1 ⫾ 0.3
7.3 ⫾ 1.0
38.3 ⫾ 4.6
1227 ⫾ 163
50.4 ⫾ 5.5
39.1 ⫾ 9.3
0.5 ⫾ 0.1
0.27 ⫾ 0.01
106 ⫾ 55
82.0 ⫾ 4.5
19.8 ⫾ 2.8
1.9 ⫾ 0.3
18.3 ⫾ 2.5
4.7 ⫾ 0.6
6.8 ⫾ 0.8
13.4 ⫾ 1.9
12.6 ⫾ 1.3
8.8 ⫾ 1.0
26.1 ⫾ 2.7
66.0 ⫾ 10.2
19.8 ⫾ 3.0
91 ⫾ 13
36.5 ⫾ 3.9
5.0 ⫾ 0.8
0.8 ⫾ 0.1
7.4 ⫾ 0.8
49.6 ⫾ 3.4

222 ⫾ 29
1.5 ⫾ 0.2
5.4 ⫾ 0.5
28.1 ⫾ 4.1
991 ⫾ 75
47.2 ⫾ 5.2
33.5 ⫾ 2.3
0.4 ⫾ 0.1
0.26 ⫾ 0.04
107 ⫾ 63
63.1 ⫾ 5.2
18.4 ⫾ 0.6
2.5 ⫾ 0.1*
13.3 ⫾ 2.0
4.0 ⫾ 0.5
6.2 ⫾ 0.8
13.7 ⫾ 1.2
11.4 ⫾ 0.7
11.7 ⫾ 1.7
19.1 ⫾ 1.3
30.2 ⫾ 4.5
19.9 ⫾ 2.8
237 ⫾ 36***
37.5 ⫾ 2.6
4.1 ⫾ 0.6
0.6 ⫾ 0.1
6.4 ⫾ 0.3
40.7 ⫾ 1.9

269 ⫾ 7
2.4 ⫾ 0.3
9.0 ⫾ 0.8
51.0 ⫾ 1.5
1381 ⫾ 85
71.9 ⫾ 4.0
40.1 ⫾ 3.5
0.7 ⫾ 0.1*
0.56 ⫾ 0.01***
412 ⫾ 260
85.9 ⫾ 3.2
21.4 ⫾ 2.5
3.0 ⫾ 0.2***
21.5 ⫾ 2.8
6.0 ⫾ 0.6
9.1 ⫾ 1.4
15.6 ⫾ 1.7
14.7 ⫾ 0.6
38.6 ⫾ 1.9**
66.9 ⫾ 7.4*
202 ⫾ 15
44.4 ⫾ 4.9***
232 ⫾ 30***
47.4 ⫾ 6.6
5.6 ⫾ 0.2
0.7 ⫾ 0.1
13.6 ⫾ 1.7*
63.2 ⫾ 6.7

460 ⫾ 11***
5.2 ⫾ 0.6***
14.7 ⫾ 1.6***
80.3 ⫾ 5.8***
1714 ⫾ 186***
98.0 ⫾ 10.9***
50.4 ⫾ 4.8
1.0 ⫾ 0.1***
0.88 ⫾ 0.14***
1062 ⫾ 610**
139 ⫾ 13***
24.0 ⫾ 2.3
3.5 ⫾ 0.2***
34.3 ⫾ 3.7***
9.8 ⫾ 1.2***
12.4 ⫾ 1.7***
17.0 ⫾ 2.1*
19.9 ⫾ 2.0***
213 ⫾ 14***
317 ⫾ 25***
3848 ⫾ 354***
63.3 ⫾ 4.6***
173 ⫾ 31**
53.6 ⫾ 5.3**
8.0 ⫾ 0.8***
1.9 ⫾ 0.3***
30.0 ⫾ 3.4***
65.3 ⫾ 9.3*

490 ⫾ 69***
4.8 ⫾ 0.7
13.0 ⫾ 1.1***
68.8 ⫾ 6.6***
1368 ⫾ 82
104.1 ⫾ 15.9***
46.1 ⫾ 7.4
0.9 ⫾ 0.1***
0.9 ⫾ 0.11***
2845 ⫾ 594***
136 ⫾ 22***
23.0 ⫾ 4.0
3.3 ⫾ 0.3***
28.6 ⫾ 2.3***
10.1 ⫾ 0.7***
16.0 ⫾ 2.2***
13.3 ⫾ 1.3
19.7 ⫾ 1.8***
159 ⫾ 24***
299 ⫾ 33***
2981 ⫾ 306***
68.3 ⫾ 8.9***
121 ⫾ 5
63.4 ⫾ 9.5***
9.0 ⫾ 0.5***
1.8 ⫾ 0.3***
29.7 ⫾ 4.3***
72.1 ⫾ 9.3***

410 ⫾ 48***
2.6 ⫾ 0.3
9.2 ⫾ 1.3
60.2 ⫾ 16.6**
1229 ⫾ 66
84.6 ⫾ 15.0**
46.6 ⫾ 10
0.7 ⫾ 0.1
0.51 ⫾ 0.04**
128 ⫾ 81
131 ⫾ 19***
20.4 ⫾ 1.1
2.8 ⫾ 0.4***
28.9 ⫾ 4.8***
7.0 ⫾ 0.2***
11.4 ⫾ 0.5***
14.1 ⫾ 1.1
16.9 ⫾ 2.8*
10.2 ⫾ 1.3
41.0 ⫾ 1.8
87.3 ⫾ 3.2
28.5 ⫾ 3.3
63.0 ⫾ 26.1
55.1 ⫾ 2.8**
14.7 ⫾ 1.2***
1.1 ⫾ 0.2
10.4 ⫾ 1.6
50.9 ⫾ 6.4

a

All measurements were made using WT C57BL/6J mice.
Control values are from naive mice. All values are given in pg analyte/mg total protein as mean ⫾ SEM.
*p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001, relative to control (baseline) values (one-way ANOVA with Bonferroni’s post hoc test). n ⫽ 4 independent experiments/time point.
b

only expression of NGF paralleled the rapid development of C5ainduced thermal hyperalgesia (30 min) in behavioral testing
(Figs. 3, 7). Indeed, NGF levels reached their peak within 30 min
of C5a injection (Fig. 8D). In contrast, all other inflammatory
mediators were upregulated at a much slower rate, showing essentially no increase at 30 min and reaching their peak values
within 2–3 h after C5a injection (Fig. 8; Table 1). Thus, the rapid
time course of NGF upregulation combined with the fact that
NGF sensitizes TRPV1 through multiple signaling mechanisms
(Chuang et al., 2001; Zhang et al., 2005b; Stein et al., 2006; Zhu
and Oxford, 2007), and that it is expressed and released by macrophages (Mallat et al., 1989; Garaci et al., 1999; Marcinkiewicz et
al., 1999; Obata et al., 2002), makes NGF a likely candidate for
mediating the C5a-induced thermal hyperalgesia. Consistent
with the latter findings, RT-PCR analysis demonstrated that NGF
was expressed in our primary cultures of mouse macrophages
(Fig. 9A).
To determine the role of NGF in C5a-induced thermal hyperalgesia, we first examined its effect on thermal sensitivity. We
found that intraplantar injection of NGF in wild-type mice induced strong thermal hyperalgesia that lasted for at least 3 h (Fig.
9B). As in the case of C5a (Fig. 3), the effect of NGF was absent in
TRPV1 KO mice (Fig. 9B). Thus, TRPV1 is a crucial effector of
signaling by both C5a and NGF in the context of thermal hyperalgesia. Next, we examined the effects of an NGF-neutralizing
antibody (anti-NGF) that had been validated by others (Wild et
al., 2007; Cheng et al., 2009; Cheng et al., 2010), and found that it
prevented NGF-induced thermal hyperalgesia (data not shown).
Moreover, administering anti-NGF, but not a control IgG, 30
min before C5a administration blocked C5a-induced thermal

hyperalgesia (Fig. 9C). This finding validates the critical role of
NGF in mediating the hyperalgesic effect of C5a (Fig. 9C). Neither IgG nor anti-NGF treatment affected the baseline (before
C5a injection) paw withdrawal latency (Fig. 9C).
NGF is thought to sensitize TRPV1 via the tropomyosinrelated kinase A (TrkA) receptor (Chuang et al., 2001; Zhang et
al., 2005b; Zhu and Oxford, 2007). Therefore, we also tested the
role of Trk signaling in C5a-induced thermal hyperalgesia. Because of the lack of commercially available isoform-selective Trk
inhibitors (Wang et al., 2008; McCarthy and Walker, 2014), we
used a potent pan-Trk inhibitor, GNF-5837 (Albaugh et al.,
2012), in these experiments. As a positive control, we demonstrated that pretreatment with GNF-5837 inhibited
NGF-induced thermal hyperalgesia (Fig. 9D). We found that
GNF-5837 inhibited the effect of C5a in a dose-dependent manner (Fig. 9E).
Finally, if NGF functions downstream of macrophage
activation in the C5a-induced signaling cascade, its pronociceptive action should theoretically be independent of
macrophages. To test this idea, we examined the effect of intraplantar administration of NGF in macrophage-depleted
mice. We found that NGF produced a rapid and strong thermal hyperalgesia in macrophage-depleted (AP20187-treated)
MAFIA mice and that this effect was similar to that produced
by NGF in wild-type mice (Fig. 10). In contrast, C5a administration had no effect in macrophage-depleted mice
(Figs. 7, 10).
Together, these data indicate that NGF is required for C5ainduced thermal hyperalgesia and that it acts downstream of
macrophage activation and upstream of TRPV1.
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Figure 9. NGF signaling is required for C5a-induced thermal hyperalgesia. A, RT-PCR shows expression of C5aR1 and NGF in primary macrophages (the housekeeping gene GAPDH serves as a
control). No RT indicates the negative control reaction for which a reverse transcription step was omitted. Hippocampal mRNA was used as a control for NGF expression (Collins and Crutcher, 1985;
Shelton and Reichardt, 1986; Ayer-LeLievre et al., 1988). B, Intraplantar injection of NGF (10 ng) produced thermal hyperalgesia in wild-type (C57BL/6J) mice (black circles; n ⫽ 6), but not in TRPV1
KO mice (red squares; n ⫽ 8). ***p ⬍ 0.001, relative to wild-type (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). C, Intraplantar administration of C5a (500 ng) induced
thermal hyperalgesia (black triangles; n ⫽ 10), and this was blocked by pretreatment with the NGF neutralizing antibody (1 g; 30 min before C5a injection; red circles; n ⫽ 16), but not by control
IgG (1 g; 30 min before C5a injection; gray squares; n ⫽ 10). All tests were performed using wild-type C57BL/6J mice. *p ⬍ 0.05, relative to C5a (two-way repeated-measures ANOVA with
Bonferroni’s post hoc test). ***p ⬍ 0.001, relative to C5a (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). D, NGF-induced thermal hyperalgesia (10 ng NGF; black squares; n ⫽
4) was prevented by pretreatment with the Trk inhibitor, GNF-5837 (500 ng; 30 min before NGF injection; red squares; n ⫽ 4). All tests were performed using wild-type C57BL/6J mice. *p ⬍ 0.05,
relative to NGF⫹Sham (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). **p ⬍ 0.01, relative to NGF⫹Sham (two-way repeated-measures ANOVA with Bonferroni’s post hoc
test). E, Thermal hyperalgesia induced by intraplantar C5a (500 ng; black circles; n ⫽ 8) was diminished by pretreatment (30 min before C5a injection) with the Trk inhibitor GNF-5837 in a
dose-dependent manner (50 ng, red squares, n ⫽ 11; 500 ng, green triangles, n ⫽ 7). All tests were performed using wild-type C57BL/6J mice. *p ⬍ 0.05, relative to C5a⫹Sham (two-way
repeated-measures ANOVA with Bonferroni’s post hoc test). ***p ⬍ 0.001, relative to C5a⫹Sham (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). Red and green asterisks
indicate the 50 and 500 ng doses of GNF-5837, respectively.

Discussion
In this study, we identify mechanisms that underlie C5a-induced
thermal hyperalgesia (Fig. 11). Our findings suggest that C5a
generated in response to injury or inflammation acts via
macrophages to initiate an intercellular signaling cascade that
ultimately causes sensitization of nociceptors to heat. This
macrophage-to-nociceptor signaling cascade recruits TRPV1 as a
key nociceptive channel that mediates C5a-induced thermal hyperalgesia. In turn, NGF serves as an essential mediator in this
cascade that acts downstream of C5aR1 and macrophages, sensitizing TRPV1 to heat via previously identified signaling mechanisms coupled to TrkA activation (Chuang et al., 2001; Zhang et
al., 2005b; Zhu and Oxford, 2007). The pathway described here
represents a novel signaling module that underlies interactions
between the complement system and nociceptive neurons in eliciting pain hypersensitivity (Fig. 11).
There has been growing recognition of the importance of the
complement cascade in the nervous system (Brennan et al., 2012;

Stephan et al., 2012). Several of its components contribute to the
regulation of neuronal development, synapse plasticity, and remodeling (Stephan et al., 2012). However, excessive activation of
the complement system and overproduction of C5a, as well as of
C3a, have been linked to neurotoxic processes that occur after
stroke, spinal cord injury, and in several chronic neurological
disorders, such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer’s disease (Veerhuis et al., 2011; Brennan et al.,
2012).
The role of the complement system is particularly important
in regulating nociceptor function and pain processing (Li et al.,
2007; Ren and Dubner, 2010). Many components of the complement cascade are upregulated in chronic pain states, and pharmacologic or genetic targeting of the complement system
produce analgesic effects (Clark et al., 2006; Levin et al., 2008;
Wang et al., 2011; Moriconi et al., 2014). Here, we demonstrated
an important role of the complement fragment C5a in the CFA
model of inflammatory pain. CFA-induced hyperalgesia was ac-
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Figure 10. Macrophages are not necessary for NGF-induced thermal hyperalgesia. Heat
sensitivity was examined before (baseline time ⫽ 0 h) and after intraplantar injection of NGF
(10 ng) in macrophage-depleted MAFIA mice (red circles; n ⫽ 5) and wild-type C57BL/6J mice
(black squares; n ⫽ 8). **p ⬍ 0.01, relative to baseline (two-way repeated-measures ANOVA
with Bonferroni’s post hoc test). ***p ⬍ 0.001, relative to baseline (two-way repeatedmeasures ANOVA with Bonferroni’s post hoc test). Black and red asterisks indicate wild-type and
AP20187-treated MAFIA mice, respectively. Heat sensitivity before and after intraplantar injection of C5a in macrophage-depleted MAFIA mice is shown for comparison (green triangles;
n ⫽ 8; replotted from Fig. 7D).

companied by significant upregulation of C5a in the affected area
(Fig. 2A), and both KO and pharmacological inhibition of C5aR1
markedly diminished CFA-induced thermal and mechanical hyperalgesia, although with a slightly different time dependence
(Fig. 1). This difference suggests that C5a/C5aR1 play distinct
roles during the onset and maintenance of CFA-induced mechanical and thermal sensitization, respectively. Although the
doses of C5a required to induce thermal hyperalgesia (Fig. 3) are
consistent with the previous work (Jang et al., 2010; Moriconi et
al., 2014), they exceed the levels of C5a found in the skin after
incision (Jang et al., 2011) or CFA treatment (Fig. 2A) (1–1.7
ng/mg protein). However, a number of confounding factors,
such as C5a diffusion, its rapid metabolism by serum and cellsurface peptidases, and C5a internalization upon binding to its
receptor (Oppermann and Götze, 1994; Monk et al., 2007; Manthey et al., 2009), help to explain why administration of relatively
high doses of C5a is required. Overall, our findings corroborate
previous studies that highlight a critical role of C5a in pain processing (Levine et al., 1985; Clark et al., 2006; Griffin et al., 2007;
Jang et al., 2011; Liang et al., 2012; Moriconi et al., 2014).
How does C5a produce a state of pain hypersensitivity? Our
results suggest that resident macrophages are the first cells to
respond to C5a elevation in the periphery, and that they are major
players in mediating the pronociceptive effects of C5a. First, using the C5aR1 KO-validated antibody, we showed that in skin
tissue C5aR1 was present almost exclusively in macrophages
(Fig. 4). Second, using Ca 2⫹ imaging, we demonstrated that
functional C5aR1 is expressed in primary macrophages. Specifically, C5aR1 activation was coupled to a robust G␤␥- and PLCdependent [Ca 2⫹]i response (Figs. 5, 6). Third, and most
importantly, conditional ablation of macrophages in transgenic
mice expressing a suicide gene in macrophages/monocytes abolished C5a-induced hyperalgesia (Fig. 7). It has been previously
proposed that the pronociceptive action of C5a depends on neutrophils (Ting et al., 2008). This report relied on systemically
administered cytotoxic agent vinblastine to deplete neutrophils.
However, this agent is highly toxic to a broad range of cell types
in addition toneutrophils and is known to kill many other immune cells, including monocytes and macrophages (Chen and
Schooley, 1970; Martin et al., 1981). In contrast, the MAFIA
mouse model used in our study allows specific and reversible

Figure 11. Proposed model describes the signaling pathways activated by C5a in macrophages and nociceptors in the periphery to produce pain hypersensitivity. Activation of the
complement cascade in response to injury, infection, or inflammation leads to generation of C5a
among other complement products. C5a activates C5aR1 in macrophages, which triggers G␤␥and PLC-dependent robust Ca 2⫹ mobilization from intracellular (most likely IP3-sensitive)
Ca 2⫹ stores. Although not tested in our work, it has been reported that C5a induces IP3 synthesis in macrophages (Roach et al., 2008). C5a-induced macrophage activation results in mobilization of NGF and NGF/TrkA-dependent sensitization of TRPV1 in nociceptive fibers to heat.
Gray arrows indicate additional signaling pathways and immune cell types (neutrophils and
mast cells) that can be affected by C5a but were not specifically tested in our work.

elimination of monocytes and monocyte-derived cells (e.g., macrophages), but not of neutrophils or other immune cells (Burnett
et al., 2004; Lindauer et al., 2009; Cho et al., 2014). By treating
MAFIA mice with the dimerizing compound AP20187, we
achieved ⬃85% depletion of resident skin macrophages (Fig. 7).
Macrophage-depleted mice displayed normal baseline sensitivity
to noxious heat (Fig. 7D) and developed strong NGF-induced
thermal hyperalgesia (Fig. 10), suggesting that the described
treatment did not impair the ability of these mice to sense and
respond to noxious heat. Yet, C5a-induced sensitization to heat
was eliminated by macrophage ablation. Combined with the observation that subcutaneous C5aR1 is expressed primarily in
macrophages, these findings imply that macrophages are essential for C5a-induced thermal hyperalgesia. Future studies will
determine whether macrophages also play a crucial role in C5ainduced mechanical sensitization.
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Macrophages have been implicated in various aspects of inflammatory and neuropathic pain (Sorkin and Schafers, 2007;
Ren and Dubner, 2010). They can profoundly affect nociceptor
excitability by releasing soluble factors that either activate or sensitize nociceptive neurons. Our findings suggest that NGF serves
as a crucial mediator of macrophage-to-nociceptor signaling in
the case of C5a-induced thermal hyperalgesia. First, NGF is expressed in macrophages (Figure 9A) (Mallat et al., 1989; Garaci et
al., 1999; Marcinkiewicz et al., 1999). Second, out of a broad
panel of inflammatory mediators (28 total) tested in our work,
only NGF was rapidly upregulated in the affected area in response
to C5a, reaching its maximum within 30 min after the C5a injection (Fig. 8; Table 1). This time course parallels the rapid development of C5a-induced thermal hyperalgesia (Figs. 3, 7, 9, 10).
Other inflammatory mediators monitored in the same assay either reached their peak levels at much later times (2–3 h after C5a
injection) or were not affected by C5a (Fig. 8; Table 1). Third,
subcutaneously administered NGF mimicked the development
of thermal hyperalgesia triggered by C5a, including its critical
dependence on TRPV1 (Figs. 3, 7, 9, 10). Thus, C5a and NGF
target the same nociceptive channel. Fourth, and most importantly, C5a-induced thermal hyperalgesia was nearly abolished by
pretreatment with an NGF-neutralizing antibody (Fig. 9C). Fifth,
a Trk inhibitor, GNF-5837, strongly diminished the effect of C5a
(Fig. 9E). Finally, NGF-induced thermal hyperalgesia was insensitive to macrophage depletion (Fig. 10), indicating that NGF acts
downstream of macrophages in the C5a-induced pronociceptive
signaling cascade (Fig. 11).
The finding that NGF serves as a critical mediator of C5a
hyperalgesic signaling is consistent with the importance of NGF
in many aspects of acute and chronic pain (Stucky et al., 1999; Ji
et al., 2002; Pezet and McMahon, 2006). On a long-time scale
(days/weeks), NGF contributes to pain hypersensitivity by regulating expression of nociceptive ion channels and neuropeptides,
by triggering oxidative mechanisms, and by stimulating aberrant
axonal sprouting (Pezet and McMahon, 2006; Mantyh et al.,
2011; Eskander et al., 2015). On a short-time scale (seconds/
minutes), NGF sensitizes nociceptors to heat by regulating the
surface expression and activation properties of TRPV1 (Chuang
et al., 2001; Zhang et al., 2005b). It is likely that NGF-dependent
potentiation of TRPV1 is an essential component of the C5ainduced signaling that ultimately leads to heat sensitization described here (Fig. 11). Indeed, TRPV1 was required for the
hyperalgesic effects of C5a (Fig. 3), and NGF acted downstream
of C5a and upstream of TRPV1 (Fig. 9). Mechanisms underlying
the NGF-dependent sensitization of TRPV1 have been well established by others, and hence have not been additionally
investigated in our work. They involve activation of the phosphatidylinositol 3-kinase and PLC signaling cascades downstream of
TrkA, which facilitates TRPV1 trafficking to the plasma membrane and also sensitizes the receptor to heat, capsaicin, and other
activating stimuli (Chuang et al., 2001; Zhang et al., 2005b; Zhu
and Oxford, 2007).
Our findings that NGF is required for C5a-induced thermal
hyperalgesia do not rule out a potential involvement of other
inflammatory mediators upregulated by C5a (Fig. 8; Table 1).
Indeed, some of these mediators, such as TNF-␣, IL-1␤, IL-6,
MCP-1, MIP-1␣, and PGE2, are known to be secreted by macrophages and to sensitize nociceptive neurons by acting on
TRPV1 and other ion channels (Nathan, 1987; Gold et al.,
1996; Marchand et al., 2005; Ji et al., 2014). Therefore, it is
possible that, in addition to NGF, some of these mediators also
contributed to the observed hyperalgesic effects of C5a,
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although likely at later time points (Fig. 8). Future studies
will determine their roles in the pronociceptive effects of
C5a.
In conclusion, we have shown that the complement system
product C5a induces a hyperalgesic response by triggering
macrophage-to-nociceptor signaling and by recruiting two
prominent pain molecules, NGF and TRPV1. Pharmacologic targeting of C5aR1 may prove to be a useful strategy for treating
various chronic pain conditions, including those associated with
aberrant activity of NGF and TRPV1.
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